Return on Assets (ROA): 7.15%
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 7.15% is 21% below its 5-year average of 9.07%, near the low end of its 5-year range (4.09%–24.87%).
As of Saturday, June 27, 2026. 4.38% above its 12-month average of 6.85%.
GSK Return on Assets (ROA) Chart
Annual fiscal-year return on assets; no daily interpolation.
GSK Average Return on Assets (ROA) Chart
GSK Current vs Average Return on Assets (ROA) Chart
GSK Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
7.15%
RETURN ON ASSETS (ROA) AVG TTM
6.85%
RETURN ON ASSETS (ROA) AVG 3Y
11.28%
RETURN ON ASSETS (ROA) AVG 5Y
9.07%
RETURN ON ASSETS (ROA) AVG 10Y
7.74%
RETURN ON ASSETS (ROA) AVG 15Y
7.17%
RETURN ON ASSETS (ROA) AVG 20Y
10.10%
CURRENT VS TTM AVG
+4.38%
CURRENT VS 3Y AVG
-36.61%
CURRENT VS 5Y AVG
-21.20%
CURRENT VS 10Y AVG
-7.58%
CURRENT VS 15Y AVG
-0.21%
CURRENT VS 20Y AVG
-29.20%
GSK Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GSK plc (GSK) | $105.20B | 7.15% | 6.85% | 11.28% | 9.07% |
| Medtronic plc (MDT)vs › | $103.66B | 5.16% | 5.13% | 4.62% | 4.65% |
| Bristol-Myers Squibb Company (BMY)vs › | $117.46B | 8.41% | -0.92% | 3.28% | 1.99% |
| McKesson Corporation (MCK)vs › | $89.39B | 5.78% | 5.08% | 5.08% | 2.52% |
| HCA Healthcare, Inc. (HCA)vs › | $86.89B | 11.06% | 10.43% | 10.23% | 10.42% |
| Elevance Health Inc. (ELV)vs › | $85.82B | 4.17% | 4.89% | 5.25% | 5.41% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $124.70B | 16.38% | 6.37% | 11.74% | 14.58% |
| Stryker Corporation (SYK)vs › | $127.39B | 7.21% | 6.88% | 7.02% | 6.41% |
| CVS Health Corp. (CVS)vs › | $133.13B | 1.16% | 1.25% | 1.93% | 2.38% |
| Cigna Corporation (CI)vs › | $74.81B | 4.10% | 2.99% | 3.50% | 3.82% |
Asset Efficiency
ROA
7.2%
ROE
25.2%
Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for GSK plc (GSK)?
- The return on assets (ROA) for GSK stock is 7.15%.
- Is GSK plc's return on assets (ROA) high or low?
- The return on assets (ROA) of 7.15% is 21% below its 5-year average of 9.07%, near the low end of its 5-year range (4.09%–24.87%).
- What is the TTM average return on assets (ROA) for GSK plc (GSK)?
- The TTM average return on assets (ROA) for GSK stock is 6.85%.
- What is the 3Y average return on assets (ROA) for GSK plc (GSK)?
- The 3Y average return on assets (ROA) for GSK stock is 11.28%.
- What is the 5Y average return on assets (ROA) for GSK plc (GSK)?
- The 5Y average return on assets (ROA) for GSK stock is 9.07%.
- What is the 10Y average return on assets (ROA) for GSK plc (GSK)?
- The 10Y average return on assets (ROA) for GSK stock is 7.74%.
- What is the 15Y average return on assets (ROA) for GSK plc (GSK)?
- The 15Y average return on assets (ROA) for GSK stock is 7.17%.
- What is the 20Y average return on assets (ROA) for GSK plc (GSK)?
- The 20Y average return on assets (ROA) for GSK stock is 10.10%.
GSK Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 9.37% |
| 2024-12-31 | 4.33% |
| 2023-12-31 | 6.55% |
| 2022-12-31 | 24.87% |
| 2021-12-31 | 4.09% |
| 2020-12-31 | 5.23% |
| 2019-12-31 | 4.40% |
| 2018-12-31 | 6.24% |
| 2017-12-31 | 2.72% |
| 2016-12-31 | 1.54% |
| 2015-12-31 | 15.76% |
| 2014-12-31 | 6.78% |
| 2013-12-31 | 12.92% |
| 2012-12-31 | 10.85% |
| 2011-12-31 | 12.81% |
| 2010-12-31 | 3.89% |
| 2009-12-31 | 12.90% |
| 2008-12-31 | 11.68% |
| 2007-12-31 | 16.84% |
| 2006-12-31 | 21.08% |
| 2005-12-31 | 17.24% |
| 2004-12-31 | 17.02% |
| 2003-12-31 | 18.70% |
| 2002-12-31 | 17.62% |
| 2001-12-31 | 14.11% |
| 2000-12-31 | 19.28% |
| 1999-12-31 | 17.37% |
| 1998-12-31 | 19.64% |
| 1997-12-31 | 21.93% |
| 1996-12-31 | 24.02% |
Related Metrics
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels